|
| 37184523 | Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study. | Hepatol Commun | 2023 |
| 35317387 | A Novel Tissue Atlas and Online Tool for the Interrogation of Small RNA Expression in Human Tissues and Biofluids. | Front Cell Dev Biol | 2022 |
| 36398137 | Cessation of Nucleoside/Nucleotide Analogue Therapy in Chronic Hepatitis B HBeAg-Negative Patients. | Gastroenterol Hepatol (N Y) | 2022 |
| 35485347 | Virus reactivation in a non-cirrhotic HBV patient requiring liver transplantation after cessation of nucleoside analogue therapy. | Antivir Ther | 2021 |
| 31606455 | Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis. | Clin Gastroenterol Hepatol | 2020 |
| 33681680 | Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study. | Hepatol Commun | 2020 |
| 31754685 | Don't Stop Post-Sustained Virologic Response Hepatocellular Carcinoma Surveillance Just Yet! | Clin Infect Dis | 2020 |
| 32813292 | Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States. | Aliment Pharmacol Ther | 2020 |
| 30815273 | Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel. | BMJ Open Gastroenterol | 2019 |
| 31802987 | Update on the Treatment of Hepatitis C Virus Infection in Patients With Cirrhosis. | Gastroenterol Hepatol (N Y) | 2019 |
| 31402538 | CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. | Liver Int | 2019 |
| 30980576 | Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis. | J Viral Hepat | 2019 |
| 30859149 | A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. | Hepatol Commun | 2019 |
| 29306043 | Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. | Clin Gastroenterol Hepatol | 2018 |
| 29991938 | Management of Patients Who Have Achieved Sustained Virologic Response for Hepatitis C Virus Infection. | Gastroenterol Hepatol (N Y) | 2018 |
| 29878430 | Editorial: chronic hepatitis B combination therapy-emerging success as proof-of-concept for future hepatitis B eradication? | Aliment Pharmacol Ther | 2018 |
| 30775622 | Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease. | Kidney Int Rep | 2018 |
| 30775621 | Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease. | Kidney Int Rep | 2018 |
| 30411079 | Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct-Acting Antivirals for Hepatitis C. | Hepatol Commun | 2018 |
| 29461687 | Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis. | Liver Int | 2018 |
| 27418632 | Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. | Gut | 2017 |
| 28203284 | Novel emerging treatments for hepatitis C infection: a fast-moving pipeline. | Therap Adv Gastroenterol | 2017 |
| 29038644 | Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection. | Gastroenterol Hepatol (N Y) | 2017 |
| 27790729 | All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. | Aliment Pharmacol Ther | 2017 |
| 26189820 | microRNA changes in liver tissue associated with fibrosis progression in patients with hepatitis C. | Liver Int | 2016 |
| 26509462 | HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. | Liver Int | 2016 |
| 27904836 | Pulmonary complications of transcatheter arterial chemoembolization for hepatocellular carcinoma. | World J Respirol | 2016 |
| 27565882 | Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. | Gastroenterology | 2016 |
| 27532829 | A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. | N Engl J Med | 2016 |
| 27140229 | Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. | Eur J Gastroenterol Hepatol | 2016 |
| 27035078 | An Unexpected Pulmonary Complication Following Transcatheter Arterial Chemoembolization of a Small Hepatocellular Carcinoma. | J Clin Gastroenterol | 2016 |
| 26976799 | Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. | Gastroenterology | 2016 |
| 24814388 | Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study. | Liver Int | 2015 |
| 31041008 | Genotype 3: Treat now or wait for something better? | Clin Liver Dis (Hoboken) | 2015 |
| 26487939 | Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. | J Gastrointest Oncol | 2015 |
| 25846014 | Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. | Hepatology | 2015 |
| 25909356 | Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. | Ann Intern Med | 2015 |
| 25942724 | Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. | JAMA | 2015 |
| 25614962 | All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. | Hepatology | 2015 |
| 25790160 | A genome sequencing program for novel undiagnosed diseases. | Genet Med | 2015 |
| 25251156 | Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. | Hepatology | 2015 |
| 25080450 | Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. | Gut | 2015 |
| 24184810 | Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. | Gastroenterology | 2014 |
| 30992933 | The dawn of a new era in the treatment of HCV infection: A view from the USA. | Clin Liver Dis (Hoboken) | 2014 |
| 26356545 | Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study. | J Clin Transl Hepatol | 2014 |
| 25078309 | Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. | Lancet | 2014 |
| 24871445 | Advances in newly developing therapy for chronic hepatitis C virus infection. | Front Med | 2014 |
| 24720702 | Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. | N Engl J Med | 2014 |
| 24725238 | Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. | N Engl J Med | 2014 |
| 24126682 | Novel therapeutic approaches for hepatitis C. | Clin Pharmacol Ther | 2014 |